The Shelburne Group | Context Therapeutics
21375
portfolio_page-template-default,single,single-portfolio_page,postid-21375,ajax_fade,page_not_loaded,,select-theme-ver-4.2,vertical_menu_enabled,wpb-js-composer js-comp-ver-7.6,vc_responsive
 

Context Therapeutics

Context Therapeutics is dedicated to discovering, acquiring, and developing novel compounds to treat hormone responsive cancers.

Their lead program is Apristor (onapristone xr), an investigational drug for progesterone receptor positive (PR+) breast cancer. Up to 70% of breast cancers express progesterone receptor (PR). If your cancer is PR+, Apristor could be an option for you.

Visit Client Website